Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
QLQ-C30: Global Health Status
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Summary and Conclusions
HER2 Expression by Central Assessment in Tumors with Locoregional Progression on T-DM1 Prior to Surgery
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Primary Results
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Final Analysis
Presented By Sara Hurvitz at 2019 ASCient Disposition
Neoadjuvant Trastuzumab, Pertuzumab and Chemotherapy versus T-DM1 and Pertuzumab in HER2-Positive Breast Cancer: <br />Final Outcome Results from the <br />Phase 3 KRISTINE Study (NCT02131064)
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Slide 16
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Slide 17
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Background
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
KRISTINE Study Design
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Adverse Events Overview
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Grade ≥3 AEs with >2% Difference in Incidence <br />Between Treatment Arms (Overall Study)
KRISTINE Investigators
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Disclosures
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Event-Free Survival
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
EFS Events
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Invasive Disease-Free Survival
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting
Invasive Disease-Free Survival by pCR Status and Treatment
Presented By Sara Hurvitz at 2019 ASCO Annual Meeting